Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.

Moderna, a Massachusetts-based pharmaceutical firm that sits at No. 37 on Fortune’s 2024 World’s Most Admired Companies list is recruiting adult participants for Nova 301, its Phase 3 clinical trial evaluating an investigational norovirus vaccine called mRNA-1403. The first U.S. participant in the global, randomized controlled trial received their dose in September